adenoviral vector based gene therapy (Institut Pasteur of Shanghai)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameadenoviral vector based gene therapy (Institut Pasteur of Shanghai)
Drug Alias Namecetuximab expressed gene therapy (Institute Pasteur Of Shanghai)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesInstitute of Immunology and Infection, Chinese Academy of Sciences Shanghai
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitute of Immunology and Infection, Chinese Academy of Sciences Shanghai
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A